Does 1 + Beat 2 +? And ADC-After-ADC

Category - mBC

Choosing First-Line Therapy in HER2+ Metastatic Disease

The Frontline Face-Off: DB-09, PATINA, and HER2CLIMB-05

DESTINY-Breast09 Explained: Why 40 Months PFS Matters

Redefining the Horizon: Is Cure Possible in HER2+ mBC?

The New 1st Line Reality in HER2+ mBC: Why the Strongest Tool Goes First

PATINA, HER2CLIMB-05 & the Maintenance Therapy Debate

Vigilance is Key: Managing ILD with T-DXd

The 1st Line Decision: Why T-DXd is Redefining the Start

Beyond CLEOPATRA: When the 1L Standard Falls Short

Cleopatra’s Survival Impact in HER2+ Metastatic Breast Cancer

Induction, Maintenance, or Both? Rethinking HER2+ mBC Treatment Strategy

The T-DXd Tradeoff: Balancing Breakthrough Efficacy with ILD Risk